One-Time Income Resulted in Strong 1H FY18 Performance – Crysvita Is Key Driver.
We reiterate our “Equal-weight” rating on the stock post 1H FY18 (YE Dec-18) earnings KHK reported a decline in 1H FY18 sales (-2.0% to ¥1b) mainly...
560 Views
Japan Pharma: Upcoming Catalysts & Event Driven Trading Ideas
Takeda Pharmaceutical Co Ltd (4502 JP), Shionogi & Co Ltd (4507 JP), Nippon Shinyaku Co Ltd (4516 JP) , Sumitomo Dainippon Pharma Co (4506 JP),...
316 Views
Sosei & Kyowa Hakko Kirin: Positive News on GPCR Drugs
Kyowa Hakko Kirin's (4151 JP) announcement that “moga” – mogamulizumab (KW-0761) – has met its primary endpoint (PFS) in Phase III trials for...
405 Views